Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, Louis Mauriac, Mario Campone, Michèle Tubiana-Hulin, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Véronique Becette, Pierre Farmer, Sylvie André, Chaitanya R Acharya, Sayan Mukherjee, David Cameron, Jonas Bergh, Joseph R Nevins, Richard D Iggo

Research output: Contribution to journalArticlepeer-review

Abstract

We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.
Original languageEnglish
Pages (from-to)1071-8
Number of pages8
JournalThe Lancet Oncology
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2007

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cyclophosphamide
  • Disease-Free Survival
  • Epirubicin
  • Female
  • Fluorouracil
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genetic Testing
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Oligonucleotide Array Sequence Analysis
  • Patient Selection
  • Predictive Value of Tests
  • ROC Curve
  • Receptors, Estrogen
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Taxoids
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial'. Together they form a unique fingerprint.

Cite this